The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
M Yuan, LL Huang, JH Chen, J Wu, Q Xu - Signal transduction and …, 2019 - nature.com
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[HTML][HTML] Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
[HTML][HTML] Current and emergent therapy options for advanced squamous cell lung cancer
Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is
challenging to treat because of specific clinicopathologic characteristics, which include older …
challenging to treat because of specific clinicopathologic characteristics, which include older …
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
H Akamatsu, K Ninomiya, H Kenmotsu… - International journal of …, 2019 - Springer
According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
Tyrosine kinase receptors in oncology
J Esteban-Villarrubia, JJ Soto-Castillo, J Pozas… - International journal of …, 2020 - mdpi.com
Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential
role in the molecular pathways, leading to cell survival and differentiation. Consequently …
role in the molecular pathways, leading to cell survival and differentiation. Consequently …
[HTML][HTML] EGFRvIII: An Oncogene with Ambiguous Role
A Rutkowska, E Stoczyńska-Fidelus, K Janik… - Journal of …, 2019 - hindawi.com
Epidermal growth factor receptor variant III (EGFR vIII) seems to constitute the perfect
therapeutic target for glioblastoma (GB), as it is specifically present on up to 28–30% of GB …
therapeutic target for glioblastoma (GB), as it is specifically present on up to 28–30% of GB …
Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare
Background We studied trends in lung cancer treatment cost over time by phase of care,
treatment strategy, age, stage at diagnosis, and histology. Methods Using the Surveillance …
treatment strategy, age, stage at diagnosis, and histology. Methods Using the Surveillance …